To the Editor We read with interest the Editorial by Naik and Lowes1 and agree that there is an urgent need to advance knowledge in hidradenitis suppurativa (HS). We wish to highlight a particularly vulnerable but overlooked population with HS: those who are pregnant or seeking to become pregnant.
Even though HS disproportionately affects women of reproductive age, there remain significant knowledge gaps regarding the effect of HS and its management on fertility, pregnancy, and maternal and fetal outcomes. Other chronic inflammatory diseases have been shown to affect pregnancy in important ways, including by increasing rates of preterm birth and pregnancy loss.2 Despite these findings, HS—similarly inflammatory, associated with numerous medical comorbidities, and treated with systemic agents (including biologic therapies)—is underrepresented in the literature.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Adelekun AA, Micheletti RG, Hsiao JL. Creation of a Registry to Address Knowledge Gaps in Hidradenitis Suppurativa and Pregnancy. JAMA Dermatol. Published online January 08, 2020. doi:10.1001/jamadermatol.2019.4162
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: